These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 38191924)

  • 1. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.
    Marra A; Chandarlapaty S; Modi S
    Nat Rev Clin Oncol; 2024 Mar; 21(3):185-202. PubMed ID: 38191924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating the HER2 pathway in early and advanced breast cancer.
    Pegram MD
    Hematol Oncol Clin North Am; 2013 Aug; 27(4):751-65, viii. PubMed ID: 23915743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.
    Gajria D; Chandarlapaty S
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):263-75. PubMed ID: 21342044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.
    Schroeder RL; Stevens CL; Sridhar J
    Molecules; 2014 Sep; 19(9):15196-212. PubMed ID: 25251190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.
    Rexer BN; Arteaga CL
    Crit Rev Oncog; 2012; 17(1):1-16. PubMed ID: 22471661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2-directed therapy: current treatment options for HER2-positive breast cancer.
    Ahmed S; Sami A; Xiang J
    Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting HER2-positive breast cancer: advances and future directions.
    Swain SM; Shastry M; Hamilton E
    Nat Rev Drug Discov; 2023 Feb; 22(2):101-126. PubMed ID: 36344672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of HER2-positive breast cancer: current status and future perspectives.
    Arteaga CL; Sliwkowski MX; Osborne CK; Perez EA; Puglisi F; Gianni L
    Nat Rev Clin Oncol; 2011 Nov; 9(1):16-32. PubMed ID: 22124364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Her2 a paradigm for targeted therapy].
    Marijon H; André F
    Bull Cancer; 2011 Oct; 98(9):1011-7. PubMed ID: 21684838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.
    Mohd Sharial MSN; Crown J; Hennessy BT
    Ann Oncol; 2012 Dec; 23(12):3007-3016. PubMed ID: 22865781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.
    Elster N; Collins DM; Toomey S; Crown J; Eustace AJ; Hennessy BT
    Breast Cancer Res Treat; 2015 Jan; 149(1):5-15. PubMed ID: 25542271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
    de Melo Gagliato D; Jardim DL; Marchesi MS; Hortobagyi GN
    Oncotarget; 2016 Sep; 7(39):64431-64446. PubMed ID: 26824988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
    Veeraraghavan J; De Angelis C; Reis-Filho JS; Pascual T; Prat A; Rimawi MF; Osborne CK; Schiff R
    Breast; 2017 Aug; 34 Suppl 1(Suppl 1):S19-S26. PubMed ID: 28687441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
    Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
    Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
    Huang Y; Fu P; Fan W
    Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W; Esteva FJ
    Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies.
    Whenham N; D'Hondt V; Piccart MJ
    Clin Breast Cancer; 2008 Feb; 8(1):38-49. PubMed ID: 18501058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.